Marginal Zone Lymphoma
2 competing products in clinical development for Marginal Zone Lymphoma.
Pipeline by Phase
Phase 22
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Copanlisib + Rituximab | Celltrion | Phase 2 | Active | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | Terminated | 52 |